KPTI Karyopharm Therapeutics
- 1.080
- 0.0000.00%
- 1.109
- +0.029+2.72%
Karyopharm Therapeutics News
Karyopharm Therapeutics (KPTI) Gets a Buy From Piper Sandler
Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)
Barclays Gives a Buy Rating to Karyopharm Therapeutics (KPTI)
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN)
Piper Sandler Reaffirms Their Buy Rating on Karyopharm Therapeutics (KPTI)
RBC Capital Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI)
Hold Rating on Karyopharm Therapeutics: Evaluating Q3 Results, Impact of PAP and Prospects of Xpovio in Myelofibrosis Treatment
RBC Capital Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $3
Karyopharm Therapeutics Analyst Ratings
RBC Cuts Price Target on Karyopharm Therapeutics to $3 From $4, Keeps Outperform Rating
Analysts' Top Healthcare Picks: Karyopharm Therapeutics (KPTI), Outlook Therapeutics (OTLK)
Buy Rating Recommended for Karyopharm Therapeutics Amid Strong 3Q Results and Promising Xpovio Sales
Karyopharm Therapeutics (KPTI) Gets a Buy From Piper Sandler
RBC Capital Reaffirms Their Buy Rating on Karyopharm Therapeutics (KPTI)
Analysts Are Bullish on These Healthcare Stocks: Karyopharm Therapeutics (KPTI), Pliant Therapeutics (PLRX)
Morgan Stanley Maintains Equal-Weight on Karyopharm Therapeutics, Lowers Price Target to $4
Karyopharm Therapeutics Analyst Ratings
Analysis
Price Target
No Data
